Compare AVXL & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVXL | GBLI |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.7M | 404.2M |
| IPO Year | 2013 | 2010 |
| Metric | AVXL | GBLI |
|---|---|---|
| Price | $4.49 | $27.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $22.00 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 5.3K |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.00% |
| EPS Growth | N/A | ★ 70.49 |
| EPS | N/A | ★ 1.30 |
| Revenue | N/A | ★ $441,187,000.00 |
| Revenue This Year | N/A | $4.18 |
| Revenue Next Year | N/A | $8.77 |
| P/E Ratio | ★ N/A | $21.35 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.86 | $25.88 |
| 52 Week High | $13.99 | $37.00 |
| Indicator | AVXL | GBLI |
|---|---|---|
| Relative Strength Index (RSI) | 55.96 | 44.83 |
| Support Level | $3.60 | $27.57 |
| Resistance Level | $4.88 | $29.72 |
| Average True Range (ATR) | 0.27 | 0.50 |
| MACD | 0.05 | -0.07 |
| Stochastic Oscillator | 78.01 | 16.77 |
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance world-wide. The company's two segments are: Penn-America and Non-Core Operations. The Penn-America segment offers specialty property and casualty products designed for its Wholesale Commercial, Specialty Products, InsurTech, and Assumed Reinsurance product offerings. These product lines are offered in the excess and surplus lines marketplace; and Non-Core Operations segment contains lines of business that have been de-emphasized or are no longer being written. The majority of its revenue is from the the Penn-America segment . Geographically, the majority is from California.